Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PN-943 in moderate to severe active ulcerative colitis
NCT04504383Phase 2Completed
- Sponsor
- Protagonist Therapeutics, Inc.
- Start
- Aug 2020
- Primary completion
- Feb 2023
- Modality
- Peptides, Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of PN-943 in ulcerative colitis (UC), sponsored by Protagonist Therapeutics, Inc.. Started Aug 2020; status: completed.
02
Drugs
PN-943
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04504383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04504383.